Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more
Green Cross Lab Cell Corporation - Asset Resilience Ratio
Green Cross Lab Cell Corporation (144510) has an Asset Resilience Ratio of 0.18% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Green Cross Lab Cell Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Lab Cell Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.00 Billion | 0.18% |
| Total Liquid Assets | ₩1.00 Billion | 0.18% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Lab Cell Corporation maintains only 0.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Green Cross Lab Cell Corporation Industry Peers by Asset Resilience Ratio
Compare Green Cross Lab Cell Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
|
U2Bio Co., Ltd.
KQ:221800 |
Diagnostics & Research | 68.57% |
Annual Asset Resilience Ratio for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Green Cross Lab Cell Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | ₩-9.81K | ₩578.35 Billion | +0.00pp |
| 2023-12-31 | 0.00% | ₩-39.99K | ₩665.17 Billion | -7.00pp |
| 2022-12-31 | 7.00% | ₩47.37 Billion | ₩676.53 Billion | +3.90pp |
| 2021-12-31 | 3.10% | ₩20.01 Billion | ₩645.57 Billion | -12.76pp |
| 2020-12-31 | 15.86% | ₩12.11 Billion | ₩76.36 Billion | -4.10pp |
| 2019-12-31 | 19.97% | ₩13.59 Billion | ₩68.06 Billion | -29.42pp |
| 2018-12-31 | 49.39% | ₩28.28 Billion | ₩57.27 Billion | -20.32pp |
| 2017-12-31 | 69.70% | ₩38.58 Billion | ₩55.36 Billion | -2.60pp |
| 2016-12-31 | 72.30% | ₩39.41 Billion | ₩54.51 Billion | +49.76pp |
| 2015-12-31 | 22.53% | ₩3.80 Billion | ₩16.86 Billion | -- |